GLP-1 Medications in 2025: New Evidence on Weight Loss, Liver Health, and Choosing the Right Option
Asare B. Christian, MD, MPH · 2026-10-10
GLP-1 Medications in 2025: New Evidence on Weight Loss, Liver Health, and Choosing the Right Option
The Short Answer
GLP-1 medicine advanced substantially in 2025. Head-to-head trial data now rank the leading injectable options, semaglutide showed it can improve liver fibrosis in fatty liver disease, and combination gut-hormone therapies produced some of the deepest weight losses yet recorded in randomized trials. For patients, the takeaway is that medication choice is increasingly individual, based on metabolic profile, liver health, and treatment response rather than one-size-fits-all prescribing.
What the Evidence Shows
Tirzepatide versus semaglutide: the first major head-to-head
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide in adults with obesity or overweight without diabetes over 72 weeks. Tirzepatide achieved an average weight loss of 20.2 percent compared with 13.7 percent for semaglutide [1]. The difference reflects tirzepatide's dual activity at both GIP and GLP-1 receptors. Both are effective medications; one demonstrated greater efficacy in this trial population.
Semaglutide treated the liver, not just the scale
The ESSENCE phase 3 trial evaluated once-weekly semaglutide in patients with moderate to advanced fibrosis from metabolic dysfunction-associated steatohepatitis, the progressive form of fatty liver disease. Semaglutide resolved active liver inflammation without worsening fibrosis in 62.9 percent of patients and significantly improved fibrosis in 37.0 percent [2]. This is important for the large number of patients with obesity who also carry liver disease, previously treated mainly through weight loss itself.
Combination therapy set a new bar
The REDEFINE-1 trial tested a fixed-dose combination of cagrilintide, a long-acting amylin analog, with semaglutide. The combination achieved average weight loss of 22.7 percent at 68 weeks, exceeding single-agent therapy [3]. Amylin and GLP-1 regulate satiety through complementary pathways, and activating both is emerging as the next frontier in metabolic medicine. These therapies are not yet approved, but the trajectory is clear.
Clinical Interpretation
The clinical significance is precision. Choosing among these medications now depends on concrete variables: whether fatty liver disease is present, how much weight reduction is needed for metabolic goals, tolerability of side effects, and response measured objectively over the first months of treatment. GLP-1 therapy also requires a maintenance plan, because weight regain after stopping is well documented and strength preservation matters during rapid weight loss.
Limitations and Uncertainties
Trials run 48 to 72 weeks; lifelong outcomes data are still accumulating. Gastrointestinal side effects are common and dose-dependent. Muscle mass loss accompanies rapid weight loss, which argues for protein optimization and resistance training alongside medication. Cost and access vary. None of these medications is appropriate for cosmetic weight loss in people without a medical indication.
Who These Medications Are For
Appropriate candidates generally have obesity, or overweight with at least one weight-related medical condition, and have not achieved goals through lifestyle care alone. They are not for people seeking minor weight reduction, and they require medical supervision, monitoring, and a plan for long-term maintenance.
How Aether Medicine Approaches Metabolic Care
Our ASSESS, RESTORE, OPTIMIZE framework treats GLP-1 therapy as one tool inside a complete metabolic program: comprehensive metabolic and liver assessment, individualized medication selection when indicated, nutrition and strength preservation, and longitudinal monitoring of body composition and metabolic markers.
Frequently Asked Questions
Which is better, tirzepatide or semaglutide?
In SURMOUNT-5, tirzepatide produced greater average weight loss. Better for you depends on your health history, side-effect tolerance, insurance coverage, and treatment goals. That is an individualized medical decision.
Can GLP-1 medications help fatty liver disease?
The ESSENCE trial showed semaglutide resolved steatohepatitis in most patients and improved fibrosis in a substantial minority. Liver evaluation and monitoring belong in metabolic care.
Will I regain weight if I stop?
Studies show most people regain a meaningful share of lost weight after discontinuation without a maintenance plan. That is why structured tapering, metabolic monitoring, and lifestyle systems matter as much as the medication itself.
Do I need to exercise on these medications?
Yes. Resistance training and adequate protein help preserve muscle during weight loss and support long-term metabolic health.
Where can I get GLP-1 and metabolic care near Philadelphia?
Aether Medicine is located at 660 American Ave, #103, King of Prussia, PA 19406, serving the Main Line and Greater Philadelphia. Call 484-806-1101 to discuss a consultation.
References
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025. https://doi.org/10.1056/NEJMoa2416394
- Sanyal AJ, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025. https://doi.org/10.1056/NEJMoa2413258
- Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025. https://doi.org/10.1056/NEJMoa2502081
About the Author
Asare B. Christian, MD, MPH, ABPMR, ABAARM, is Founder and Medical Director of Aether Medicine, double board-certified in Physical Medicine and Rehabilitation and Anti-Aging and Regenerative Medicine, with training at Johns Hopkins, Harvard Medical School, and MIT Sloan. He serves as a Voting Member of the U.S. FDA Pharmacy Compounding Advisory Committee (PCAC), term 2026-2030. This federal advisory role is separate from Aether Medicine's commercial services and does not imply FDA endorsement of the practice or any therapy.
A Metabolic Plan Built Around Your Biology
If you are considering GLP-1 therapy or want a comprehensive metabolic evaluation in King of Prussia, the Main Line, or Greater Philadelphia, call 484-806-1101 or visit https://aethermedicine.com.
Educational information only. This article is a draft for physician review and is not individualized medical advice. Consult your physician before starting, stopping, or changing any treatment.